Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03682029 · ClinicalTrials.gov registry record · NA
Epigenetics, Vitamin C, and Abnormal Blood Cell Formation - Vitamin C in Patients With Low-Risk Myeloid Malignancies
A NA study of Myelodysplastic Syndromes and Cytopenia, sponsored by Rigshospitalet, Denmark.
- Active
- Registry status
- NA
- Development phase
- 109
- Enrollment target
- 5
- Study locations
NCT03682029 is a NA study of Myelodysplastic Syndromes and Cytopenia that is active but no longer recruiting, run by Rigshospitalet, Denmark. The registered enrollment target is 109 participants, below the 284-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (62% lower). The trial reports 5 study locations across 3 states.
The verdict
NCT03682029, a NA study of Myelodysplastic Syndromes and Cytopenia, is active but no longer recruiting, sponsored by Rigshospitalet, Denmark.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 109 participants
- Enrollment target
- 5
- Study locations
Study Summary
The primary purpose of this multi-centre, randomized, placebo-controlled, double-blind phase II study is to investigate if oral vitamin C may change the biology of low-risk myeloid malignancies; i.e., clonal cytopenia of undetermined significance (CCUS), low-risk myelodysplastic syndromes (MDS), and chronic myelomonocytic leukemia (CMML)-0/1 by reversing the epigenetic changes characteristic of these disease entities. The epigenetic regulator TET2 is the gene most often affected in CCUS. Preclinical studies have shown that active demethylation by the TET enzymes is dependent on vitamin C, and the investigators and collaborators have shown that plasma vitamin C levels are exceedingly low in hematological cancer patients but are easily corrected by oral vitamin C. This study is part of an array of EVITA studies aimed at clarifying whether the standard of care of patients with myeloid malignancies should be changed and oral vitamin C supplement added to the treatment recommendations.
Conditions Studied
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT Vitamin C (ascorbic acid)
Study Locations (5)
Other
- Aalborg University Hospital - Aalborg
- Herlev University Hospital - Copenhagen
- Odense University Hospital - Odense
California
- Keck Hospital of University of Southern California - Los Angeles
N/A = Not Applicable
- Rigshospitalet - Copenhagen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2017-11-21 |
| Est. Completion | 2025-09-27 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03682029
The ClinicalTrials.gov registry entry for NCT03682029 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 284-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (62% lower). The listed sponsor is Rigshospitalet, Denmark, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Myelodysplastic Syndromes appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03682029 reports 5 study locations spanning 3 distinct geographic areas - top geographies include Other, California, N/A = Not Applicable.
Frequently Asked Questions
What is clinical trial NCT03682029 about?
NCT03682029 is a clinical study titled "Epigenetics, Vitamin C, and Abnormal Blood Cell Formation - Vitamin C in Patients With Low-Risk Myeloid Malignancies". The primary purpose of this multi-centre, randomized, placebo-controlled, double-blind phase II study is to investigate if oral vitamin C may change the biology of low-risk myeloid malignancies; i.e., clonal cytopenia of undetermined significance (CCUS), low-risk myelodysplastic syndromes (MDS), and...
What is the current status of trial NCT03682029?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 109 participants. The study started on 2017-11-21. Estimated completion is 2025-09-27.
What conditions does trial NCT03682029 study?
This clinical trial studies the following conditions: Myelodysplastic Syndromes, Cytopenia, Chronic Myelomonocytic Leukemia-1.
What interventions are being tested in trial NCT03682029?
The interventions under investigation include: Placebo (OTHER), Vitamin C (ascorbic acid) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03682029?
This trial is sponsored by Rigshospitalet, Denmark, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03682029 being conducted?
This trial has 5 study locations across California, N/A = Not Applicable. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Telehealth Advance Care Planning Intervention
RECRUITING · NA
-
Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS
RECRUITING · NA
-
HEME Home Transfusion Program
RECRUITING · NA
-
Home Blood Transfusions
RECRUITING · NA
-
Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in MDS
RECRUITING · NA
-
Mosaic Trial for Stem Cell Transplant Recipients
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.